[1]Bannai S, Kitamura E. Adaptive enhancement of cystine and glutamate uptake in human diploid fibroblasts in culture[J]. Biochim Biophys Acta, 1982, 721(1): 1-10.
[2]Sharma MK, Seidlitz EP, Singh G. Cancer cells release glutamate via the cystine/glutamate antiporter[J]. Biochem Biophys Res Commun, 2010, 391(1): 91-95.
[3]Koppula P, Zhang Y, Shi J, et al. The glutamate/cystine antiporter SLC7A11/xCT enhances cancer cell dependency on glucose by exporting glutamate[J]. J Biol Chem, 2017, 292(34): 14240-14249.
[4]Liu X, Nie L, Zhang Y, et al. Actin cytoskeleton vulnerability to disulfide stress mediates disulfidptosis[J]. Nat Cell Biol, 2023, 25(3): 404-414.
[5]Liu X, Olszewski K, Zhang Y, et al. Cystine transporter regulation of pentose phosphate pathway dependency and disulfide stress exposes a targetable metabolic vulnerability in cancer[J]. Nat Cell Biol, 2020, 22(4): 476-486.
[6]Stockwell BR. Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications[J]. Cell, 2022, 185(14): 2401-2421.
[7]Ji X, Qian J, Rahman SMJ, et al. xCT (SLC7A11)mediated metabolic reprogramming promotes nonsmall cell lung cancer progression[J]. Oncogene, 2018, 37(36): 5007-5019.
[8]Bridges RJ, Natale NR, Patel SA. System xc- cystine/glutamate antiporter: an update on molecular pharmacology and roles within the CNS[J]. Br J Pharmacol, 2012, 165(1): 20-34.
[9]Koppula P, Zhuang L, Gan B. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy[J]. Protein Cell, 2021, 12(8): 599-620.
[10]Lee J, Roh JL. SLC7A11 as a gateway of metabolic perturbation and ferroptosis vulnerability in cancer[J]. Antioxidants (Basel), 2022, 11(12): 2444.
[11]Gao J, Li Y, Song R. SIRT2 inhibition exacerbates p53mediated ferroptosis in mice following experimental traumatic brain injury[J]. Neuroreport, 2021, 32(12): 1001-1008.
[12]Luo Y, Gao X, Zou L, et al. Bavachin induces ferroptosis through the STAT3/P53/SLC7A11 axis in osteosarcoma cells[J]. Oxid Med Cell Longev, 2021, 2021: 1783485.
[13]Guan Z, Chen J, Li X, et al. Tanshinone ⅡA induces ferroptosis in gastric cancer cells through p53mediated SLC7A11 downregulation[J]. Biosci Rep, 2020, 40(8): BSR20201807.
[14]Chen L, Qiao L, Bian Y, et al. GDF15 knockdown promotes erastininduced ferroptosis by decreasing SLC7A11 expression[J]. Biochem Biophys Res Commun, 2020, 526(2): 293-299.
[15]Robert SM, Buckingham SC, Campbell SL, et al. SLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant glioma[J]. Sci Transl Med, 2015, 7(289): 289ra86.
[16]Liu XX, Li XJ, Zhang B, et al. MicroRNA26b is underexpressed in human breast cancer and induces cell apoptosis by targeting SLC7A11[J]. FEBS Lett, 2011, 585(9): 1363-1367.
[17]Guo W, Zhao Y, Zhang Z, et al. Disruption of xCT inhibits cell growth via the ROS/autophagy pathway in hepatocellular carcinoma[J]. Cancer Lett, 2011, 312(1): 55-61.
[18]Li S, Lu Z, Sun R, et al. The role of SLC7A11 in cancer: friend or foe?[J]. Cancers (Basel), 2022, 14(13): 3059.
[19]赵亦非, 王宝华. miR375靶向SLC7A11调控口腔鳞癌细胞增殖、侵袭的研究分析[J]. 解放军预防医学杂志, 2019, 37(5): 145-147.
[20]Patel D, Kharkar PS, Gandhi NS, et al. Novel analogs of sulfasalazine as system x-c antiporter inhibitors: Insights from the molecular modeling studies[J]. Drug Dev Res, 2019, 80(6): 758-777.
[21]Srensen MF, Heimisdóttir SB, Srensen MD, et al. High expression of cystineglutamate antiporter xCT (SLC7A11) is an independent biomarker for epileptic seizures at diagnosis in glioma[J]. J Neurooncol, 2018, 138(1): 49-53.
[22]Roh JL, Kim EH, Jang H, et al. Aspirin plus sorafenib potentiates cisplatin cytotoxicity in resistant head and neck cancer cells through xCT inhibition[J]. Free Radic Biol Med, 2017, 104: 1-9.
[23]Yamaguchi I, Yoshimura SH, Katoh H. High cell density increases glioblastoma cell viability under glucose deprivation via degradation of the cystine/glutamate transporter xCT (SLC7A11)[J]. J Biol Chem, 2020, 295(20): 6936-6945.
[24]Teramoto K, Katoh H. The cystine/glutamate antiporter xCT is a key regulator of EphA2 S897 phosphorylation under glucoselimited conditions[J]. Cell Signal, 2019, 62: 109329.
[25]Gu Y, Albuquerque CP, Braas D, et al. mTORC2 regulates amino acid metabolism in cancer by phosphorylation of the cystineglutamate antiporter xCT[J]. Mol Cell, 2017, 67(1): 128-138.e7.
[26]Jyotsana N, Ta KT, DelGiorno KE. The role of cystine/glutamate antiporter SLC7A11/xCT in the pathophysiology of cancer[J]. Front Oncol, 2022, 12: 858462.
[27]Ye LF, Chaudhary KR, Zandkarimi F, et al. Radiationinduced lipid peroxidation triggers ferroptosis and synergizes with ferroptosis inducers[J]. ACS Chem Biol, 2020, 15(2): 469-484.
[28]Liu X, Zhang Y, Zhuang L, et al. NADPH debt drives redox bankruptcy: SLC7A11/xCTmediated cystine uptake as a doubleedged sword in cellular redox regulation[J]. Genes Dis, 2021, 8(6): 731-745.
[29]Hu N, Hu WH, Zhou SL, et al. SLC7A11 negatively associates with mismatch repair gene expression and endows glioblastoma cells sensitive to radiation under low glucose conditions[J]. Neoplasma, 2021, 68(6): 1147-1156.
[30]Wei BY, Kong W, Mou XY, et al. Comprehensive analysis of tumor immune infiltration associated with endogenous competitive RNA networks in lung adenocarcinoma[J]. Pathol Res Pract, 2019, 215(1): 159-170.
[31]Ma L, Chen T, Zhang X, et al. The m6A reader YTHDC2 inhibits lung adenocarcinoma tumorigenesis by suppressing SLC7A11dependent antioxidant function[J]. Redox Biol, 2021, 38: 101801.
[32]Iida Y, OkamotoKatsuyama M, Maruoka S, et al. Effective ferroptotic smallcell lung cancer cell death from SLC7A11 inhibition by sulforaphane[J]. Oncol Lett, 2021, 21(1): 71.
[33]Chen RS, Song YM, Zhou ZY, et al. Disruption of xCT inhibits cancer cell metastasis via the caveolin1/βcatenin pathway[J]. Oncogene, 2009, 28(4): 599-609.
[34]Polewski MD, ReveronThornton RF, Cherryholmes GA, et al. SLC7A11 overexpression in glioblastoma is associated with increased cancer stem celllike properties[J]. Stem Cells Dev, 2017, 26(17): 1236-1246.
[35]Miyoshi S, Tsugawa H, Matsuzaki J, et al. Inhibiting xCT improves 5Fluorouracil resistance of gastric cancer induced by CD44 variant 9 expression[J]. Anticancer Res, 2018, 38(11): 6163-6170.
[36]Zhang L, Huang Y, Ling J, et al. Overexpression of SLC7A11: a novel oncogene and an indicator of unfavorable prognosis for liver carcinoma[J]. Future Oncol, 2018, 14(10): 927-936.
[37]Wada F, Koga H, Akiba J, et al. High expression of CD44v9 and xCT in chemoresistant hepatocellular carcinoma: Potential targets by sulfasalazine[J]. Cancer Sci, 2018, 109(9): 2801-2810.
[38]张萌, 刘旭明, 麦皓尘, 等. SLC7A11在KRAS突变胰腺癌中的表达及临床意义[J]. 实用医学杂志, 2022, 38(24): 3125-3128, 3134.
[39]Chen X, Yu C, Kang R, et al. Cellular degradation systems in ferroptosis[J]. Cell Death Differ, 2021, 28(4): 1135-1148.
[40]Lin W, Wang C, Liu G, et al. SLC7A11/xCT in cancer: biological functions and therapeutic implications[J]. Am J Cancer Res, 2020, 10(10): 3106- 3126.
[41]Zhu JH, De Mello RA, Yan QL, et al. MiR1395p/SLC7A11 inhibits the proliferation, invasion and metastasis of pancreatic carcinoma via PI3K/Akt signaling pathway[J]. Biochim Biophys Acta Mol Basis Dis, 2020, 1866(6): 165747.
[42]Yang Q, Li K, Huang X, et al. lncRNA SLC7A11AS1 promotes chemoresistance by blocking SCFβTRCPmediated degradation of NRF2 in pancreatic cancer[J]. Mol Ther Nucleic Acids, 2020, 19: 974-985.
[43]Tang R, Hua J, Xu J, et al. The role of ferroptosis regulators in the prognosis, immune activity and gemcitabine resistance of pancreatic cancer[J]. Ann Transl Med, 2020, 8(21): 1347.
[44]王建国, 陶耀业, 陈成, 等. SLC7A11蛋白在肝内胆管细胞癌组织中的表达及临床意义[J]. 浙江临床医学, 2021, 23(10): 1394-1396.
[45]朱明镒. SLC7A11在结直肠癌中的表达及其与微卫星不稳定的相关性研究[D]. 承德: 承德医学院, 2022.
[46]Dai Z, Huang Y, Sadee W, et al. Chemoinformatics analysis identifies cytotoxic compounds susceptible to chemoresistance mediated by glutathione and cystine/glutamate transport system xc-[J]. J Med Chem, 2007, 50(8): 1896-1906.
[47]Xu X, Zhang X, Wei C, et al. Targeting SLC7A11 specifically suppresses the progression of colorectal cancer stem cells via inducing ferroptosis[J]. Eur J Pharm Sci, 2020, 152: 105450.
[48]Lee N, Carlisle AE, Peppers A, et al. xCTdriven expression of GPX4 determines sensitivity of breast cancer cells to ferroptosis inducers[J]. Antioxidants (Basel), 2021, 10(2): 317.
[49]Hong T, Lei G, Chen X, et al. PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCAproficient ovarian cancer[J]. Redox Biol, 2021, 42: 101928.
[50]杜红飞, 庞雪利, 阳燕, 等. SLC7A11在膀胱癌组织及细胞中的表达及意义[J]. 现代肿瘤医学, 2021, 29(21): 3792-3797.
[51]Drayton RM, Dudziec E, Peter S, et al. Reduced expression of miRNA27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11[J]. Clin Cancer Res, 2014, 20(7): 1990-2000.
[52]任宗涛, 马永良, 卫书飞, 等. 铁死亡相关蛋白SLC7A11及GPX4在肾细胞癌中的表达及意义[J]. 现代肿瘤医学, 2023, 31(2): 323-326. |